



TO: Pharmacies, Physicians, Nurse Practitioners, Physician Assistants, Long Term Care Providers, Clinics and Hospitals
RE: Wegovy Coverage for Risk Reduction of Major Adverse Cardiac Event (MACE) in Adults with Established Cardiovascular Disease and either Obesity or Overweight

Effective February 3, 2025, the Department will reimburse for new prescriptions for Wegovy through the pharmacy benefit when prescribed to reduce the risk of Major Adverse Cardiac Event (MACE) in adults 18 and older with established cardiovascular disease and either obesity or overweight. This prescription will be reimbursed under the HUSKY Health Programs (A, B, C and D) for those meeting the specified criteria.

Established Cardiovascular disease includes presenting a medical history of 1 or more of the following:

- History of Myocardial Infarction
- History of Ischemic or Hemorrhagic Stroke
- History of Symptomatic Peripheral Arterial Disease

Wegovy will **NOT** be covered:

- Exclusively for weight management, or
- Type 1 or Type 2 diabetes, or
- For those who are also diagnosed with New York Heart Association Class IV Heart Failure

The prescriber is required to complete and submit a prior authorization (PA) request form for Wegovy for members meeting the criteria above for a diagnosis indicating MACE and presenting with either obesity or overweight each time new therapy is requested and annually thereafter.

The prior authorization form will be available to providers on February 3, 2025 and will be found at www.ctdssmap.com under the Pharmacy Information tab and under the

Pharmacy Program Publications panel. The PA form titled Wegovy for MACE Risk Reduction Prior Authorization Form will detail criteria necessary for coverage.

The prescriber is advised that specific information is required to be submitted on the PA form. Any PA form submitted without the required information will be denied.